Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
View Patent ↗The invention provides a controlled release oral solid formulation comprising (a) a controlled release component comprising core comprising levodopa and/or an ester of levodopa or salts thereof, wherein the core is coated with a layer of a muco-adhesive polymer and externally coated with a layer of an enteric coated polymer; and (b) a decarboxylase inhibitor component.
1. A controlled release oral solid formulation comprising
(a) a controlled release component comprising a core comprising levodopa and/or an ester of levodopa or salts thereof, wherein the core is coated with a first layer comprising a rate-controlling polymer; the first layer is coated with a muco-adhesive layer comprising a dimethylaminoethyl methacrylate copolymer and the muco-adhesive layer is coated with a layer of an enteric coating polymer; and
(b) an immediate release component comprising levodopa and/or an ester of levodopa or salts thereof; and
wherein the controlled release component is formulated as a mini-tablet, bead, or granule and produces an in vivo levodopa plasma profile following oral administration of the controlled release oral solid formulation to a subject under fasting conditions comprising:
(a) a levodopa plasma concentration corresponding to maximum levodopa plasma concentration (C max ) occurring within 6 hours after administration of the dosage form;
(b) a time to reach 50% C max of less than one hour; and
(c) wherein the in vivo plasma level of levodopa is maintained at 50% C max or above for at least 5.0 hours.
2. The controlled release oral solid formulation of claim 1 wherein the immediate release component (b) is formulated as a mini-tablet, bead, or granule.
3. The controlled release oral solid formulation of claim 1 further comprising a decarboxylase inhibitor.
4. The controlled release oral solid formulation of claim 1 , wherein the formulation is encapsulated in a capsule.
5. The controlled release oral solid formulation of claim 1 , wherein the muco-adhesive layer comprising a dimethylaminoethyl methacrylate copolymer further comprises a polymer selected from the group consisting of polycarbophil, carbomer, cellulosics, chitosan, diethylaminodextran, diethyl aminoethyldextran, polygalactosamine, polylysine, polyomithine, prolamine, polyimine, hyaluronic acid, sodium alginate, sodium carboxymethylcellulose (sodium CMC), and alginate, or a combination thereof.
6. The controlled release oral solid formulation of claim 1 , wherein the rate-controlling polymer comprises cellulose acetate or ethylcellulose.
7. The controlled release oral solid formulation of claim 6 , wherein the rate-controlling polymer comprises cellulose acetate and copovidone.
8. The controlled release oral solid formulation of claim 1 , wherein the enteric coating polymer comprises one or more methacrylic acid copolymers.
9. The controlled release oral solid formulation of claim 1 , wherein the ester of levodopa is selected from the group consisting of ethyl (2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoate (levodopa ethyl ester), levodopa butyl ester, and levodopa methyl ester.
10. The controlled release oral solid formulation of claim 9 , wherein the ester of levodopa is a salt selected from the group consisting of an octanoate salt, myristate salt, succinate salt, succinate dihydrate salt, fumarate salt, or fumarate dihydrate salt.
11. The controlled release oral solid formulation of claim 1 , wherein the controlled release component (a) has an in vitro dissolution profile with less than 20% release of the levodopa or ester of levodopa at about pH 1.0 within two hours using a USP I dissolution method at a speed of 75 and after two hours of testing in the dissolution fluid of about pH 1.0 changing the dissolution to a fluid with a pH of about 7.0, the controlled release component will exhibit an extended release over at least 4 to 8 hours.
12. The controlled release formulation of claim 11 , wherein the controlled release component (a) has an in vitro dissolution profile with less than 10% release of the levodopa or ester of levodopa at about pH 1.0 within two hours.
13. The controlled release formulation of claim 1 , wherein the in vivo plasma level of levodopa is maintained at 50% C max or above for at least 5.5 hours.
14. The controlled release formulation of claim 1 , wherein the in vivo plasma level of levodopa is maintained at 50% C max or above for at least 6.0 hours.
15. The controlled release formulation of claim 1 , wherein the in vivo plasma level of levodopa is maintained at 50% C max or above for at least 6.5 hours.
16. The controlled release formulation of claim 1 , wherein the in vivo plasma level of levodopa is maintained at 50% C max or above for at least 7.0 hours.
17. A method of treating Parkinson's disease or primary parkinsonism comprising, administering to the subject an effective amount of the controlled release oral solid formulation of claim 1 .
18. The controlled release oral solid formulation of claim 1 wherein the controlled release component is a bead exhibiting a size between 0.8 to 1.2 mm.
19. The controlled release oral solid formulation of claim 1 wherein the controlled release component is a bead that passes through a 12 mesh screen but may be retained on a 18, 24, or 25 mesh screen.
20. The controlled release oral solid formulation of claim 1 wherein the controlled release component is a bead that passes through a 14 mesh screen but may be retained on a 18, 24, or 25 mesh screen.
21. The controlled release oral solid formulation of claim 1 wherein the controlled release component is a bead that passes through a 16 mesh screen but may be retained on a 18, 24, or 25 mesh screen.
22. The controlled release oral solid formulation of claim 1 wherein the levodopa, and/or ester of levodopa, and/or salts thereof are dispersed throughout the core or layered on a sugar sphere.